Patent US4725669A successfully refreshed from Google Patents.
US4725669A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay for detecting infection by human T-cell lymphotropic virus-III
Assignee: Harvard University
•
Filing: 1984-11-09
•
Granted: 1988-02-16
•
Expires: 2004-11-09
Abstract
Abstract A first glycoprotein having a molecular weight of approximately 120,000 daltons in the H9/HTLV-III cell line, of which approximately 90,000 daltons is the unglycosylated moiety, is obtained from cells infected with human T-cell leukemia virus, type III. A second glycoprotein having a molecular weight of aproximately 160,000 daltons is also obtained from such cells, of which approximately 90,000 daltons is the unglycosylated moiety and is substantially identical to the unglycosylated moiety of the first glycoprotein. The presence, in a biological specimen, of either of these glycoproteins or of the unglycosylated moiety is indicative of the presence of cells infected by human T-cell leukemia virus. An assay for the glycoprotein or its unglycosylated moiety is a useful diagnostic procedure for determining such infection in biological specimens.
Inventors
- 👤 Myron E. Essex
- 👤 Tun-Hou Lee
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; G01N33/56988; C12; C12N; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16111; C12N2740/16122; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/974; Y10S530/00; Y10S530/82; Y10S530/826; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
71 words
A substantially pure polypeptide having an antigenic determinant or determinants immunologically cross-reactive with determinants of a first glycoprotein having a molecular weight of approximately 120,000 daltons, said glycoprotein having substantially the same antigenic determinants as a second glycoprotein having a molecular weight of approximately 160,000 daltons, of which approximately 90,000 daltons is the molecular weight of the unglycosylated moiety, said glycoproteins being obtained from cells infected with human T-cell lymphotrophic virus-III.
Claim 2
Dependent Claim
71 words
A substantially pure polypeptide having an antigenic determinant or determinants immunologically cross-reactive with determinants of a first glycoprotein having a molecular weight of approximately 120,000 daltons, said glycoprotein having substantially the same antigenic determinants as a second glycoprotein having a molecular weight of approximately 160,000 daltons, of which approximately 90,000 daltons is the molecular weight of the unglycosylated moiety, said glycoproteins being obtained from cells infected with human T-cell lymphotrophic virus-III.
Claim 3
Dependent Claim
18 words
The polypeptide of claim 1 which is the first or second HTLV-III-associated cell surface glycoprotein of claim 1,
Claim 4
Dependent Claim
22 words
A polypeptide as claimed in claim 1 which comprises the unglycosylated moiety of the first or second HTLV-III-associated glycoprotein of claim 1.
Claim 5
Dependent Claim
29 words
A polypeptide as claimed in claim 1 which is obtained from HTLV-III infected H9 cells, from LAV infected NC37 cells, from Molt 3 cells, or from HUT 78 cells.
Claim 6
Dependent Claim
24 words
A polypeptide as claimed in claim 1 which comprises an anti-idiotypic antibody having an antigenic determinant which is immunologically cross-reactive with said first glycoprotein.
Claim 7
Dependent Claim
16 words
A polypeptide as claimed in any of claims 1, 2, or 3 which is detectably labelled.
Claim 8
Dependent Claim
17 words
The polypeptide of any of claims 1, 2 or 3 which is bound to an aqueous-insoluble phase.
Claim 9
Dependent Claim
11 words
The substantially unglycosylated moiety of the second glycoprotein of claim 1.
Claim 10
Dependent Claim
11 words
The moiety as claimed in claim 8 which is detectably labelled.
Claim 11
Dependent Claim
14 words
The moiety as claimed in claim 8 which is bound to an aqueous-insoluble phase.
References Cited (Backward Citations)
US4524027A
Cited
US4520113A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-15 | 1991-08-17 | 1992-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-15 | 1995-08-17 | 1996-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-15 | 1999-08-17 | 2000-02-16 | $7700.00 | Window Closed / Lapsed |